Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling

Current Pharmaceutical Design

Volumn 12, Issue 32, 2006, Pages 4163-4172

  Takada, H ^a   Uehara, A ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Desmuramylpeptide; Diaminopimelic acid; LPS; Muramyldipeptide; NOD1; NOD2; Peptidoglycans; Toll like receptors

Indexed keywords

BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELL RECEPTOR; DESMURAMYLPEPTIDE; DIAMINOPIMELIC ACID; GAMMA INTERFERON; HEPTANOYL GAMMA DEXTRO GLUTAMYL 2,6 DIAMINOPIMELOYL DEXTRO ALANINE; INTERLEUKIN 8; LIPID A; LIPOPEPTIDE; MESSENGER RNA; MURAMYL DIPEPTIDE; MURAMYL PEPTIDE; PEPTIDOGLYCAN; PROTEIN NOD1; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

BACTERIAL CELL WALL; CELL SURFACE; CELLULAR IMMUNITY; CPG ISLAND; CYTOKINE RELEASE; DENDRITIC CELL; GENE EXPRESSION REGULATION; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TH1 CELL;

IMMUNITY, NATURAL; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; PEPTIDOGLYCAN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 33750557881     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778743510     Document Type: Review

References (74)

1. Hoffmann JA, Kafatos FC, Janeway CA Jr, Ezekowitz RAB. Phylogenetic perspectives in innate immunity. Science 1999; 284: 1313-8.
2. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7.
3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002; 20: 197-216.
4. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
5. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J Biol Chem 1999; 274: 17406-9.
6. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11: 443-51.
7. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999; 163: 1-5.
8. Yoshimura A, Takada H, Kaneko T, Kato I, Golenbock D, Hara Y. Structural requirements of muramylpeptides for induction of Toll-like receptor 2-mediated NF-κB activation in CHO cells. J Endotoxin Res 2000; 6: 407-10.
9. Dziarski R. Gupta D. Staphylococcus aureus peptidoglycan is a Toll-like receptor 2 activator: a reevaluation. Infect Immun 2005; 73: 5212-6.
10. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Com 1974; 59: 1317-25.
11. Kotani S, Watanabe Y, Kinoshita F, Shimono T, Morisaki I, Shiba T, et al. Immunoadjuvant activities of synthetic N-acetylmuramyl-peptides or -amino acids. Biken J 1975; 18: 105-11.
12. Takada H, Kotani S. In: Stewart-Tull DES, Davies M Eds, Immunology of the bacterial cell envelope. Chichester, John Wiley & Sons 1985; 119-52.
13. Takada H, Kotani S. In: Stewart-Tull DES Ed, The theory and practical application of adjvants. Chichester, John Wiley & Sons 1995; 171-202.
14. Vidal VF, Castéran N, Riendeau CJ, Kornfeld H, Darcissac ECA, Capron A, et al. Macrophage stimulation with murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPβ and STAT1: role of CD14 and Toll-like receptors 2 and 4. Eur J Immunol 2001; 31: 1962-71.
15. Yang S, Tamai R, Akashi S, Takeuchi O, Akira S, Sugawara S, et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 2001; 69: 2045-53.
16. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-72.
17. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. J Biol Chem 2003; 278: 5509-12.
18. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic, acid. Nat Immunol 2003; 4: 702-7.
19. Girardin SE, Boneca IG, Cameiro LAM, Antignac A, Jéhanno M, Viala J, et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003; 300: 1584-7.
20. Fleck J, Mock M, Tytgat F, Nauciel C, Minck R. Adjuvant activity in delayed hypersensitivity of the peptidic part of bacterial peptidoglycans. Nature 1974; 250: 517-8.
21. Adam A. In: Synthetic Adjuvants. New York, John Wiley & Sons 1985; 1-58.
22. Goto T, Aoki H. In: Azuma I, Jollès G Eds, Immunostimulants: Now and Tomorrow. Berlin, Springer Verlag 1987; 99-108.
23. 2-(γ-D-Glutamyl)-meso-2(L),2'(D)-diaminopimelic acid as the minimal prerequisite structure of FK156: its acyl derivatives with potent immunostimulating activity. J Med Chem 1982; 25: 335-7.
24. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori M-A, Werts C, et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 2004; 5: 1000-6.
25. Netea MG, Kullberg BJ, de Jong DJ, Franke B, Sprong T, Naber THJ, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004; 34: 2052-9.
26. Netea MG, Ferwerda G, de Jong DJ, Jansen T, Jacobs L, Kramer M, et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 2005; 174: 6518-23.
27. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/Cryopyrin inflammasome. Curr Biol 2004; 14: 1929-34.
28. Ribi EE, Cantrell JL, Von Eschen KB, Schwartzman SM. Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)-D-isoglutamine (Muramyl dipeptide). Cancer Res 1979; 39: 4756-9.
29. Chedid LA, Parant MA, Audibert FM, Riveau GJ, Parant FJ, Lederer E, et al. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 1982; 35: 417-24.
30. Bloksma N, Hofhuis FM, Willers JM. Endotoxin-induced antitumor activity in the mouse is highly potentiated by muramyl dipeptide. Cancer Lett 1984; 23: 159-65.
31. Bloksma N, Hofhuis FM, Willers JM. Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin. Cancer Immunol Immunother 1985; 19: 205-10.
32. Tsujimoto M, Kotani S, Shiba T, Kusumoto S, Hasegawa A, Kiso M, et al. Regressive action with induction of hemorrhagic necrosis of mixtures of acylated muramylpeptides and synthetic, low toxic lipid A analogs on Meth A fibrosarcoma. Adv Biosci 1988; 68: 151-65.
33. Takada H, Galanos C. Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice. Infect Immun 1987; 55: 409-13.
34. Takada H, Hirai H, Fujisawa T, Koga T, Ogawa T, Hamada S. Bacteroides lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed with muramyl dipeptide. J Infect Dis 1990; 162: 428-34.
35. Endo Y, Shibazaki M, Nakamura M, Takada H. Contrasting effects of lipopolysaccharides (endotoxins) from oral black-pigmented bacteria and Enterobacteriaceae on plateles, a major source of serotonin, and on histamine-forming enzyme in mice. J Infect Dis 1997; 175: 1404-12.
36. Shibazaki M, Kawabata Y, Yokochi T, Nishida A, Takada H, Endo Y. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. Infect Immun 1999; 67: 5186-91.
37. Kawabata Y, Yang S, Yokochi T, Matsushita M, Fujita T, Shibazaki M, et al. Complement system is involved in anaphylactoid reaction induced by lipopolysaccharides in muramyldipeptide-treated mice. Shock 2000; 14: 572-7.
38. Endo Y, Yokochi T, Matsushita M, Fujita T, Takada H. Complement-dependent platelet degradation and anaphylactoid shock in mice induced by lipopolysaccharide carrying the mannose homopolymer. J Endotoxin Res 2001; 7: 451-5.
39. Zhao L, Ohtaki Y, Yamaguchi K, Matsushita M, Fujita T, Yokochi T, et al. LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood 2002; 100: 3233-9.
40. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-4.
41. Parant M, Parant F, Vinit MA, Jupin C, Noso Y, Chedid L. Priming effect of muramyl peptides for induction by lipopolysaccharide of tumor necrosis factor production in mice. J Leukoc Biol 1990; 47: 164-9.
42. Le Contel C, Temime N, Charron DJ, Parant MA. Modulation of lipopolysaccharide-induced cytokine gene expression in mouse bone marrow-derived macrophages by muramyl didpeptide. J Immunol 1993; 150: 4541-9.
43. Monodane T, Kawabata Y, Yang S, Hase S, Takada H. Induction of tumour necrosis factor-α and interleukin-6 in mice in vivo and in murine peritoneal macrophages and human whole blood cells in vitro by Micrococcus luteus teichuronic acids. J Med Microbiol 2001: 50: 4-12.
44. Isobe Y. 'Streptococcus milleri' group bacteria induce anaphylactoid reaction and inflammatory cytokines in mice primed with muramyldipeptide [in Japanese]. J Dent Health 1998; 48: 170-82.
45. Yang S, Sugawara S, Monodane T, Nishijima M, Adachi Y, Akashi S, et al. Micrococcus luteus teichuronic acids activate human and murine monocytic cells in a CD14- and Toll-like receptor 4-dependent manner. Infect Immun 2001; 69: 2025-30.
46. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, et al. Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 2000; 164: 554-7.
47. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA 1999; 96: 14459-63.
48. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999; 163: 3920-7.
49. Takeuchi O, Kawai T, Mühlradt PF, Morr M, Radolf JD, Zychlinsky A, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13: 933-40.
50. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10-4.
51. Galanos C, Freudenberg MA. Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology 1993; 187: 346-56.
52. Katschinski T, Galanos C, Coumbos A, Freudenberg MA. Gamma interferon mediates Propionibacterium acnes-induced hypersensitivity to lipopolysaccharide in mice. Infect Immun 1992; 60: 1994-2001.
53. Kamijo R, Le J, Shapiro D, Havell EA, Huang S, Aguet M, et al. Mice that lack the interferon-γ receptor have profoundly altered responses to infection with Bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178: 1435-40.
54. Freudenberg MA, Kopf M, Galanos C. Lipopolysaccharide-sensitivity of interferon-γ receptor deficient mice. J Endotoxin Res 1996; 3: 291-5.
55. Takada H, Yokoyama S, Yang S. Enhancement of endotoxin activity by muramyldipeptide. J Endotoxin Res 2002; 8: 337-42.
56. Beigneux A, Huang J, Le Contel C, Heremans H, Parant MA. Differential role of interferon-gamma in the potentiating effect of muramyl peptides for enhanced responses to lipopolysaccharide in mice: effect of cyclosporine A. J Interferon Cytokine Res 1995; 15: 359-65.
57. Funayama H, Huang L, Hagiwara M, Endo Y, Takada H. In: Watanabe M, Takahashi N, Takada H Eds, Interface Oral Health Science. Amsterdam, Elsevier 2005; 209-10.
58. Takahashi N. In Watanabe M, Takahashi N, Takada H Eds, Interface oral health science. Amsterdam, Elsevier 2005; 123-30.
59. Yang S, Takahashi N, Yamashita T, Sato N, Takahashi M, Mogi M, et al. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1α, and TNF-α through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. J Immunol 2005; 175: 1956-64.
60. Nagao S, Akagawa KS, Yamada K, Yagawa K, Tokunaga T, Kotani S. Lack of response of murine peritoneal macrophages to in vitro activation by muramyl dipeptide (MDP). I. Macrophage activation by MDP is species dependent. Microbiol Immunol 1990; 34: 323-35.
61. Tsuchida K, Takemoto Y, Yamagami S, Edney H, Niwa M, Tsuchiya M, et al. Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and limulus amebocyte lysate methods. Nephron 1997; 75: 438-43.
62. Wolfer MA, Murray TF, Boons GJ, Moore J-N. The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan. J Biol Chem 2002; 277: 39179-86.
63. Uehara A, Yang S, Fujimoto Y, Fukase K, Kusumoto S, Shibata K, et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptors agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic, cells in culture. Cell Microbiol 2005; 7: 53-61.
64. Van Heel DA, Ghosh S, Butler M, Hunt K, Foxwell BMJ, Mengin-Lecreulx D, et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 2005; 35: 2471-6.
65. Bertin J, Nir W-J, Fischer CM, Tayber OV, Errada PR, Grant JR, et al. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-κB. J Biol Chem 1999; 274: 12955-8.
66. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF, et al. An induced proximity model for NF-κB activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 2000; 275: 27823-31.
67. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-κB. J Biol Chem 1999; 274: 14560-7.
68. Tada H, Aiba S, Shibata Y, Ohteki T, Takada H. Synergistic effect of Nod1 and Nod2 agonists with Toll-like receptor agonists on human dendritic cells to generate interleukin 12 and T helper type 1 cells. Infect Immun 2005; 73: 7967-76.
69. Fritz JH, Girardin SE, Fitting C, Werts C, Mengin-Lecreulx D, Caroff M, et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005; 35: 2459-70
70. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5: 800-8.
71. Napolitani G, Rinaldi A, Bertoni F, Sallusto F. Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-76.
72. Amati L, Cozzolongo R, Manghisi OG, Cuppone R, Pellegrino NM, Caccavo D, et al. The immune responsiveness in hepatitis C virus infected patients: effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells. Curr Pharm Des 2004; 10(17): 2093-100.
73. Jennings A, Tennant M. Discovery strategies in a BioPharmaceutical startup: maximising your chances of success using computational filters. Curr Pharm Des 2005; 11(3): 335-44.
74. Wang H, Raybum E, Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr Pharm Des 2005; 11(22): 2889-907.